The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Open accessAbstract
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilogram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo capsules; 2.5 mg of oral azathioprine per kilogram daily plus a placebo infusion on the standard schedule; or combination therapy with the two drugs. Patients received study medication through week 30 and could continue in a blinded study extension through week 50. RESULTS: Of the 169 patients receiving combination therapy, 96 (56.8%) were in corticosteroid-free clinical remission at week 26 (the primary end point), as compared with 75 of 169 patients (44.4%) receiving infliximab alone (P=0.02) and 51 of 170 patients (30.0%) receiving azathioprine alone (P<0.001 for the comparison with combination therapy and P=0.006 for the comparison with infliximab). Similar numerical trends were found at week 50. At week 26, mucosal healing had occurred in 47 of 107 patients (43.9%) receiving combination therapy, as compared with 28 of 93 patients (30.1%) receiving infliximab (P=0.06) and 18 of 109 patients (16.5%) receiving azathioprine (P<0.001 for the comparison with combination therapy and P=0.02 for the comparison with infliximab). Serious infections developed in 3.9% of patients in the combination-therapy group, 4.9% of those in the infliximab group, and 5.6% of those in the azathioprine group. CONCLUSIONS: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or infliximab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azathioprine monotherapy. (ClinicalTrials.gov number, NCT00094458.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationDignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationLong-Term Evolution of Disease Behavior of Crohn's Disease
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., & Gendre, J.-P. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00002 · Cited by 1,346
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Self-citationFaubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Self-citationTreatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Dubinsky, M. C., Lamothe, S., Yang, H. Y., Targan, S. R., Sinnett, D., Théorêt, Y., & Seidman, E. G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70140-5 · Cited by 996
Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
Pearson, D. C., May, G. R., Fick, G. H., & Sutherland, L. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00009 · Cited by 950
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Self-citationTiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H. A., Wirtz, S., Becker, C., Atreya, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16432 · Cited by 828
Markowitz, J., Grancher, K., Kohn, N., Lesser, M., & Daum, F. (2000) · Gastroenterology · doi:10.1053/gast.2000.18144 · Cited by 716
Irvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D., Saibil, F., & McDonald, J. W. D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 712
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., Present, D. H., Rutgeerts, P., Schölmerich, J., Stange, E. F., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31072 · Cited by 686
Self-citationHanauer, S. B., Wagner, C. L., Bala, M. V., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 608
Self-citationTravis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Self-citationPeyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Self-citationA controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Mackey, A. C., Green, L., Liang, L., Dinndorf, P., & Avigan, M. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31802f6424 · Cited by 506
Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Self-citationLichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine
Black, A. J., McLeod, H. L., Capell, H. A., Powrie, R. H., Matowe, L. K., Pritchard, S. C., Collie-Duguid, E. S. R., & Reid, D. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00007 · Cited by 374
LÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Self-citationLichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Greenberg, G., Feagan, B., Martin, F., Sutherland, L., Thomson, A., Williams, C., Nilsson, L., & Persson, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8536887 · Cited by 288
Sandborn, W. J., Tremaine, W. J., Wolf, D. C., Targan, S. R., Sninsky, C. A., Sutherland, L. R., Hanauer, S. B., McDonald, J. W. D., Feagan, B. G., Fedorak, R. N., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70445-2 · Cited by 237
Self-citationAdverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
Marehbian, J., Arrighi, H. M., Hass, S., Tian, H., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.322 · Cited by 208
Self-citationLICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., & SANDBORN, W. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04027.x · Cited by 195
Self-citationReinisch, W., Panés, J., Lémann, M., Schreiber, S., Feagan, B. G., Schmidt, S. L., Sturniolo, G. C., Mikhailova, T. L., Alexeeva, O., Sanna, L., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02024.x · Cited by 102
Self-citationImmunosuppressant Medications and Mortality in Inflammatory Bowel Disease
Lewis, J. D., Gelfand, J. M., Troxel, A. B., Forde, K. A., Newcomb, C. W., Kim, H., Margolis, D. J., & Strom, B. L. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01836.x · Cited by 97
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Self-citationLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Self-citationPeyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationMaaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Metadata
- Authors
- Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., Tang, K. L., van der Woude, C. J., & Rutgeerts, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-15
- Volume
- 362
- Issue
- 15
- Pages
- 1383-1395
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126807394
- Cited by
- 3,143
- References
- 35
- FWCI
- 104.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.